This week’s Cardiovascular update highlights regulatory approvals, late-stage clinical progress, AI-driven diagnostics, and advancing interventional cardiology technologies.
In Today’s Newsletter
Dive deeper
💓 Angiography-derived coronary physiology gains trial support [1] [14 May 2026]
https://cardiovascularnews.com/trial-data-put-coronary-physiology-on-the-cusp-of-an-inflection-point/
Context: Both trials found angiography-derived physiology non-inferior to wire-based FFR for 1-year composite outcomes.
Key point: ALL-RISE evaluated FFRangio (CathWorks) in 1,930 patients, while FAST III evaluated CAAS vFFR (Pie Medical Imaging) in 2,235 patients with intermediate coronary lesions.
Implication: May influence prescriber choice and payer reviews pending full data.
🧠 Carotid atherosclerosis common in AF breakthrough stroke [2] [EU • 14 May 2026]
https://www.healio.com/news/cardiology/20260514/carotid-atherosclerosis-common-in-af-with-breakthrough-stroke
Context: Carotid atherosclerosis was reported in about 81% of the cohort, including stenosis or occlusion and vulnerable plaques without stenosis.
Key point: RASUNOA-Prime analyzed CT angiograms from 1,464 patients with atrial fibrillation and stroke across 46 German stroke units.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.
🛡️ EmStop starts CAPTURE-2 IDE trial for TAVR embolic protection [3] [US • 18 May 2026]
https://www.prnewswire.com/news-releases/emstop-announces-initiation-of-capture-2-ide-clinical-trial-302773752.html
Context: EmStop announced first clinical cases at Mission Hospital in Asheville, North Carolina.
Key point: CAPTURE-2 is a prospective, multi-center, randomized IDE trial comparing EmStop with a currently available embolic protection system during TAVR.
Implication: Signals pipeline investment and modality expansion.
⚡ Boston Scientific Seismiq 4CE meets FRACTURE endpoints [4] [EU • 19 May 2026]
https://cardiovascularnews.com/europcr-2026-seismiq-4ce-ivl-catheter-meets-endpoints-in-fracture-trial/
Context: Seismiq 4CE met pre-specified safety and effectiveness endpoints, with 93.3% freedom from MACE at 30 days and 93.7% procedural success.
Key point: FRACTURE enrolled 420 patients with severely calcified coronary artery disease across 46 US and European sites.
Implication: May influence prescriber choice and payer reviews pending full data.
🤖 Ventripoint stacks cardiac AI validation events [5] [Global • 19 May 2026]
https://www.prnewswire.com/news-releases/cardiac-ai-diagnostics-stack-validation-wins-across-regulatory-and-commercial-fronts-302775850.html
Context: The company positioned its AI-enhanced echocardiography platform around regulatory, clinical, and commercial validation.
Key point: Ventripoint Diagnostics highlighted VMS+ 4.0 NMPA submission in China, AEPC 2026 activity in Italy, and commercial deployment support in Northern California.
Implication: Could streamline initiation and adherence via remote prescribing and logistics.
🩸 Bayer asundexian filings accepted in US and Japan [6] [US/Japan • 19 May 2026]
https://www.bayer.com/media/en-us/new-drug-applications-for-asundexian-accepted-by-us-food-and-drug-administration-under-priority-review-and-by-japans-ministry-of-health-labour-and-welfare/
Context: FDA and Japan’s MHLW accepted NDAs for asundexian, and FDA granted Priority Review.
Key point: OCEANIC-STROKE tested asundexian 50 mg once daily plus antiplatelet therapy after non-cardioembolic ischemic stroke or high-risk TIA.
Implication: May influence prescriber choice and payer reviews pending full data.
💊 AstraZeneca Baxfendy approved for hypertension [7] [US • 19 May 2026]
https://cardiovascularbusiness.com/topics/clinical/hypertension/fda-approves-first-class-hypertension-drug-astrazeneca
Context: FDA approved Baxfendy based on BaxHTN Phase 3 data showing clinically meaningful seated systolic blood-pressure reductions.
Key point: Baxfendy (baxdrostat; AstraZeneca) is an aldosterone synthase inhibitor for adults with hypertension in combination with other antihypertensive medicines.
Implication: May influence prescriber choice and payer reviews pending full data.
🖥️ ACIST Pro cleared for US cath labs [8] [US • 18 May 2026]
https://cardiovascularbusiness.com/topics/clinical/interventional-cardiology/fda-clears-next-gen-contrast-management-system-cath-lab
Context: FDA cleared Acist Pro, enabling US launch after prior launches in Japan and Europe.
Key point: ACIST Medical Systems, a Bracco company, developed Acist Pro as a next-generation contrast management system for cardiac catheterization labs.
Implication: Access programs may expand screening, initiation, and follow-up at scale.
Why it matters
- Coronary physiology tools are moving closer to routine angiography workflows, potentially lowering procedural barriers.
- Stroke prevention remains active across diagnostics, anticoagulation, and embolic protection.
- Cardiac AI companies are linking regulatory progress with hospital deployment economics.
- FDA actions this week added a new hypertension drug class and a cath-lab contrast management system.
- EuroPCR 2026 supplied pivotal device data for complex PCI and calcified coronary disease.
📚 View the full Cardiovascular archive on our research hub page
🚀 Accelerate your success. Contact us now
📂 Explore our case studies. See examples of our work.
💡 Read our insights. Learn from our latest reports and analysis
🧰 See our full range of services. Discover how we can help you.
🎯 Catch up on the Top Cardiovascular news from the past two weeks, curated by the LucidQuest team.
FAQ
What did ALL-RISE show for FFRangio (CathWorks)?
ALL-RISE reported comparable 1-year outcomes for FFRangio versus conventional wire-based FFR in patients undergoing coronary physiology assessment. [1]
What did FAST III show for CAAS vFFR (Pie Medical Imaging)?
FAST III found CAAS vFFR non-inferior to wire-based FFR for a 1-year composite endpoint in patients with intermediate coronary lesions. [1]
What is EmStop testing in CAPTURE-2?
EmStop is testing an investigational cerebral embolic protection device for capturing and removing debris during commercially available TAVR procedures. [3]
What did Bayer report for asundexian?
Bayer said US and Japanese regulators accepted NDAs for asundexian for secondary prevention after non-cardioembolic ischemic stroke or high-risk TIA. [6]
What is Baxfendy (baxdrostat)?
Baxfendy is AstraZeneca’s first-in-class aldosterone synthase inhibitor approved by FDA for hypertension in adults with other antihypertensive medicines. [7]
Entities / Keywords
FFRangio: CathWorks, Medtronic, angiography-derived FFR, coronary physiology
CAAS vFFR: Pie Medical Imaging, virtual FFR, FAST III
Atrial fibrillation breakthrough stroke: RASUNOA-Prime, carotid atherosclerosis, vulnerable plaque
EmStop: CAPTURE-2, CAPTURE-1, TAVR, cerebral embolic protection
Seismiq 4CE: Boston Scientific, coronary IVL, FRACTURE, severe coronary calcium
Ventripoint Diagnostics: VMS+ 4.0, AI echocardiography, Knowledge Based Reconstruction, NMPA
Asundexian: Bayer, FXIa inhibitor, OCEANIC-STROKE, secondary stroke prevention
Baxfendy: AstraZeneca, baxdrostat, aldosterone synthase inhibitor, hypertension
Acist Pro: ACIST Medical Systems, Bracco, contrast management, cath lab
References
- https://cardiovascularnews.com/trial-data-put-coronary-physiology-on-the-cusp-of-an-inflection-point/
- https://www.healio.com/news/cardiology/20260514/carotid-atherosclerosis-common-in-af-with-breakthrough-stroke
- https://www.prnewswire.com/news-releases/emstop-announces-initiation-of-capture-2-ide-clinical-trial-302773752.html
- https://cardiovascularnews.com/europcr-2026-seismiq-4ce-ivl-catheter-meets-endpoints-in-fracture-trial/
- https://www.prnewswire.com/news-releases/cardiac-ai-diagnostics-stack-validation-wins-across-regulatory-and-commercial-fronts-302775850.html
- https://www.bayer.com/media/en-us/new-drug-applications-for-asundexian-accepted-by-us-food-and-drug-administration-under-priority-review-and-by-japans-ministry-of-health-labour-and-welfare/
- https://cardiovascularbusiness.com/topics/clinical/hypertension/fda-approves-first-class-hypertension-drug-astrazeneca
- https://cardiovascularbusiness.com/topics/clinical/interventional-cardiology/fda-clears-next-gen-contrast-management-system-cath-lab